Back to Search
Start Over
COVID-19 vaccines: The status and perspectives in delivery points of view
- Source :
- Advanced Drug Delivery Reviews
- Publication Year :
- 2020
- Publisher :
- Elsevier B.V., 2020.
-
Abstract
- Due to the high prevalence and long incubation periods often without symptoms, the severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) has infected millions of individuals globally, causing the coronavirus disease 2019 (COVID-19) pandemic. Even with the recent approval of the anti-viral drug, remdesivir, and Emergency Use Authorization of monoclonal antibodies against S protein, bamlanivimab and casirimab/imdevimab, efficient and safe COVID-19 vaccines are still desperately demanded not only to prevent its spread but also to restore social and economic activities via generating mass immunization. Recent Emergency Use Authorization of Pfizer and BioNTech’s mRNA vaccine may provide a pathway forward, but monitoring of long-term immunity is still required, and diverse candidates are still under development. As the knowledge of SARS-CoV-2 pathogenesis and interactions with the immune system continues to evolve, a variety of drug candidates are under investigation and in clinical trials. Potential vaccines and therapeutics against COVID-19 include repurposed drugs, monoclonal antibodies, antiviral and antigenic proteins, peptides, and genetically engineered viruses. This paper reviews virology and immunology of SARS-CoV-2, alternative therapies for COVID-19 to vaccination, principles and design considerations in COVID-19 vaccine development, and the promises and roles of vaccine carriers in addressing the unique immunopathological challenges presented by the disease.<br />Graphical abstract Unlabelled Image
- Subjects :
- Vaccine delivery
and promotion of well-being
Emergency Use Authorization
MSCs, mesenchymal stem cells
Type 1 IFNs, Type 1 interferons
Pharmaceutical Science
MERS, Middle East respiratory syndrome coronavirus
02 engineering and technology
Disease
S protein, spike protein
Pandemic
Severe acute respiratory syndrome coronavirus 2
Medicine
Pharmacology & Pharmacy
Lung
NK cell, natural killer cell
CDC, Centers for Disease Control and Prevention
media_common
COVID-19, coronavirus disease 2019
NTD, N-terminal binding domain
0303 health sciences
Coronavirus disease 2019
Genetically modified virus
AD, adenovirus
Toll-like receptor, TLR
ADE, antibody-dependent enhancement
Severe acute respiratory syndrome coronavirus
Pharmacology and Pharmaceutical Sciences
021001 nanoscience & nanotechnology
Vaccination
Infectious Diseases
3.4 Vaccines
5.1 Pharmaceuticals
SARS, severe acute respiratory syndrome coronavirus
Pneumonia & Influenza
Development of treatments and therapeutic interventions
Infection
0210 nano-technology
EUA, Emergency Use Authorization
Biotechnology
Drug
CTLs, cytotoxic T lymphocytes
COVID-19 Vaccines
media_common.quotation_subject
E protein, Envelope protein
Neutralizing antibodies
ACE2, angiotensin-converting enzyme 2
SARS-CoV-2, severe acute respiratory syndrome coronavirus 2
Antiviral Agents
Article
WHO, World Health Organization
Vaccine Related
DC, dendritic cell DC
03 medical and health sciences
RBD, receptor binding domain
Immune system
Drug Development
Immunity
Biodefense
AD, AAV, adeno-associated virus
Animals
Humans
M protein, membrane protein
Immune response
ARDS, acute respiratory distress syndrome
030304 developmental biology
TMPRSS2, transmembrane protease serine
business.industry
Immunization Programs
SARS-CoV-2
Prevention
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)
COVID-19
Pneumonia
Prevention of disease and conditions
PPRs, pattern recognition receptors
N protein, nucleocapsid protein
Coronavirus disease 2019 (COVID-19)
Emerging Infectious Diseases
Good Health and Well Being
Immunology
Immunization
APC, Antigen presenting cell
LNPs, lipid nanoparticles
RSV, respiratory syncytial virus
FDA, U.S Food and Drug Administration
business
Subjects
Details
- Language :
- English
- ISSN :
- 18728294 and 0169409X
- Database :
- OpenAIRE
- Journal :
- Advanced Drug Delivery Reviews
- Accession number :
- edsair.doi.dedup.....dc2fddd3e0cdb765800a656287283f84